| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.9B | ¥1.8B | +5.6% |
| Operating Income | ¥-3.1B | ¥-2.7B | -16.1% |
| Ordinary Income | ¥-3.1B | ¥-2.7B | -13.7% |
| Net Income | ¥-2.3B | ¥-5.1B | +54.8% |
| ROE | -195.0% | 1554.5% | - |
FY2025 consolidated results: Revenue 189.6 million yen (YoY +5.6%), Operating Income -310.5 million yen (operating loss expanded -16.1%), Ordinary Income -308.3 million yen (-13.7%), Net Income attributable to owners of parent -256.9 million yen (loss narrowed +54.8%). Total assets increased substantially to 5.34 billion yen from 2.48 billion yen, primarily driven by significant capital investments in new business segments. Equity turned positive at 1.19 billion yen versus -0.30 billion yen prior year, reflecting capital injections. The company continues to experience operating losses despite revenue growth, with SG&A expenses at 423.5 million yen substantially exceeding revenue. Sports and Environment Solution segments contributed positive operating income, while Regenerative Medicine Related segment absorbed 65.0 million yen loss from initial stage investments. Cash position improved to 93.3 million yen (+73.0%), supported by 568.5 million yen financing CF inflow, though operating and free cash flows remained deeply negative.
Revenue increased 10.0 million yen to 189.6 million yen (YoY +5.6%), driven primarily by Environment Solution segment contribution of 69.5 million yen (+7.5% from 64.7 million yen prior) and Sports segment maintaining stable sales at 114.1 million yen (-0.7% from 114.9 million yen). The newly added Regenerative Medicine Related segment contributed 6.0 million yen, representing collaborative research related to exosome development with Juntendo University. Gross profit margin remained healthy at 59.2% (112.1 million yen), improving slightly from prior period, reflecting business mix shift toward higher-margin segments. However, SG&A expenses expanded to 423.5 million yen from 369.1 million yen (+14.7%), with goodwill amortization accounting for 54.4 million yen and unallocated corporate expenses reaching 244.5 million yen. The SG&A ratio deteriorated dramatically to 223.5% from 205.5%, overwhelming gross margin improvement. Operating loss expanded to -310.5 million yen from -267.1 million yen (-16.1%), with operating margin declining to -164.0% from -148.8%. Non-operating items were minimal, resulting in ordinary loss of -308.3 million yen versus -267.8 million yen prior. Extraordinary income of 31.6 million yen (source unspecified) partially offset the loss, leading to net loss of -256.9 million yen, significantly improved from prior -387.1 million yen (+54.8% reduction in loss). The net loss improvement despite operating loss deterioration reflects both extraordinary gains and lower tax expense burden. The company discontinued Web segment during the period, liquidating Asset Genius Co., Ltd. in August 2025. This represents a "revenue up / profit down" pattern, where modest top-line growth was overwhelmed by accelerating SG&A investments in new business initiatives and corporate overhead, preventing profit recovery.
Sports segment generated revenue of 114.1 million yen with operating income of 31.3 million yen (margin 27.5%), serving as the core profitable business despite slight revenue decline of 0.7% YoY. This segment operates futsal facilities and related services, with stable customer base including Tokyo Sports System Corporation. Real Estate segment recorded operating loss of 21.9 million yen (prior -10.8 million yen) despite minimal revenue, primarily reflecting advisory business structure with lumpy revenue recognition. Energy Related segment posted operating loss of 18.9 million yen (prior -15.5 million yen) as development stage business focusing on solar power facilities and grid-scale battery storage systems. Environment Solution segment achieved operating income of 8.7 million yen on revenue of 69.5 million yen (margin 12.5%), reversing prior year's operating loss of -48.8 million yen, indicating successful turnaround in industrial waste facility management operations. The prior year segment included 135.4 million yen impairment loss and 53.4 million yen goodwill amortization which substantially depressed results. Regenerative Medicine Related segment, newly launched in current period, recorded operating loss of 65.0 million yen (margin -1084.2%) on revenue of 6.0 million yen, reflecting heavy upfront investment in cell culture facility and R&D collaboration. Web segment showed minimal activity with operating loss of 0.1 million yen before liquidation. Unallocated corporate expenses totaled 244.5 million yen (prior 219.9 million yen), representing holding company overhead. The Sports segment clearly functions as the cash-generating core business contributing over 100% of consolidated positive operating income, while Environment Solution's turnaround represents positive momentum. However, losses in development-stage segments and corporate overhead overwhelm these contributions, with Regenerative Medicine requiring substantial near-term investment before revenue materialization.
[Profitability] ROE of -195.0% reflects deep negative profitability against small equity base, deteriorating from prior year. Operating margin of -164.0% indicates severe operating unprofitability with SG&A expenses at 223.5% of revenue. Gross profit margin of 59.2% shows healthy unit economics, but is insufficient to cover fixed cost structure. EBITDA margin improved to -158.4% from -178.3% as depreciation was limited to 61.2 million yen despite substantial asset base. [Cash Quality] Cash and deposits of 93.3 million yen provide 1.33x coverage against short-term debt of 70.0 million yen, indicating adequate immediate liquidity. Operating cash flow of -357.5 million yen (OCF/Net Income ratio 1.39x) shows cash consumption exceeding accounting loss by 100.6 million yen, suggesting working capital absorption. [Investment Efficiency] Asset turnover of 0.354 indicates low capital efficiency, with total assets of 534.3 million yen generating 189.6 million yen revenue. CapEx of 175.2 million yen substantially exceeded depreciation of 61.2 million yen by 28.6x ratio, reflecting aggressive growth investment phase. [Financial Health] Equity ratio improved to 22.3% from negative prior year, though remaining below conservative thresholds. Current ratio of 435.4% shows strong short-term coverage with current assets of 282.8 million yen against current liabilities of 65.0 million yen. Debt-to-equity ratio of 3.48 indicates high financial leverage with total liabilities of 414.0 million yen. Interest-bearing debt totaled 70.0 million yen (short-term borrowings), concentrated entirely in short-term maturities at 100% ratio, creating refinancing risk. Net debt position was negative at -23.3 million yen as cash exceeded borrowings. BPS recovered to 11.53 yen from negative prior period, reflecting capital restoration through financing activities.
Operating cash flow recorded outflow of 357.5 million yen, representing 1.39x net loss of 256.9 million yen, indicating cash consumption exceeded accounting loss due to working capital movements. Operating CF before working capital changes totaled -351.2 million yen, with working capital changes absorbing additional 6.3 million yen. Investing cash flow showed outflow of 171.5 million yen, entirely driven by capital expenditures of 175.2 million yen concentrated in property, plant and equipment (214.4 million yen PP&E increase on balance sheet), primarily for Regenerative Medicine cell culture facilities and grid battery storage infrastructure. Free cash flow reached negative 528.9 million yen, substantially exceeding prior year's -220.8 million yen due to combined operating loss and accelerated CapEx program. Financing cash flow provided inflow of 568.5 million yen, enabling the funding gap, though detailed composition is not disclosed beyond the net figure. This substantial financing inflow supported both operational losses and growth investments while increasing cash position by 39.3 million yen to 93.3 million yen. The cash flow structure reveals development-stage characteristics where external capital finances both operational ramp-up and facility construction, with near-term cash generation dependent on continued financing access. Working capital showed trade receivables increasing 24.4 million yen to 34.4 million yen (+253% YoY), suggesting extended collection cycles or revenue mix shift requiring monitoring. The CapEx-to-depreciation ratio of 28.6x indicates investment phase substantially ahead of existing asset base maturity, warranting scrutiny of return on invested capital as facilities commence operations.
Operating income of -310.5 million yen versus ordinary income of -308.3 million yen shows net non-operating contribution of approximately 2.2 million yen, indicating minimal impact from financial and non-operating activities. Extraordinary income of 31.6 million yen provided one-time benefit offset by extraordinary losses of 0.3 million yen (including 0.3 million yen impairment), netting 31.3 million yen extraordinary gain. This non-recurring benefit reduced pre-tax loss from -276.9 million yen to -245.3 million yen. The prior period included substantial extraordinary losses of 135.5 million yen, making year-over-year net income comparison less meaningful on recurring basis. Operating cash flow of -357.5 million yen exceeding net loss of -256.9 million yen in absolute terms (OCF/NI ratio 1.39x) indicates working capital absorption, contrasting with typical high-quality earnings where OCF exceeds net income in positive direction. Accruals represented 18.9% of total assets, elevated above typical 5-10% range, suggesting material gap between accounting earnings and cash realization timing. The goodwill amortization of 54.4 million yen within SG&A represents non-cash charge, while prior year included 53.4 million yen, indicating ongoing acquisition-related amortization burden. Environment Solution segment's turnaround from -48.8 million yen to +8.7 million yen operating income was partially driven by absence of prior year's 135.4 million yen impairment, highlighting non-recurring nature of prior loss. The earnings quality assessment reveals losses driven by legitimate operating expenses rather than accounting distortions, though one-time extraordinary gains provided cosmetic improvement to reported net loss, and working capital dynamics indicate collection or inventory timing differences warrant attention.
Full-year FY2026 guidance projects revenue of 453.0 million yen (YoY +138.9%), operating loss of -153.0 million yen (improvement from -310.5 million yen), ordinary loss of -161.0 million yen, and net loss of -170.0 million yen. Current period revenue of 189.6 million yen represents 41.9% progress against full-year guidance, slightly behind standard 50% midpoint for second-half weighted business model, suggesting H2 acceleration of 263.4 million yen (+139% H2/H1 ratio) is embedded in forecast. Operating loss of -310.5 million yen versus full-year guidance of -153.0 million yen indicates 203% consumption of budgeted loss, suggesting aggressive H2 improvement of +157.5 million yen operating income contribution is required to achieve guidance. The revenue forecast assumes substantial scale-up in Regenerative Medicine segment commercial operations and Energy Related segment project completions, while maintaining guidance for continued Sports and Environment Solution operations. Forecast dividend remains zero, consistent with loss-making status. Management assumptions include successful commissioning of cell culture facilities, grid battery storage project deliveries, and ongoing futsal facility utilization. The guidance implies quarterly operating income improvement to approximately breakeven or slight profit in H2, requiring either revenue acceleration to 263.4 million yen with maintained gross margins, or significant SG&A efficiency gains. Given H1 SG&A of 423.5 million yen, achieving full-year operating loss of only -153.0 million yen mathematically requires H2 gross profit of approximately 270.5 million yen (implying ~165 million yen H2 revenue at 59% gross margin) and H2 SG&A reduction to ~100 million yen, representing aggressive cost discipline versus H1 run rate. The forecast embeds high execution risk around new business revenue ramps and cost control, particularly in Regenerative Medicine and corporate overhead categories.
The company paid zero dividend for both interim and full-year periods, maintaining consistent no-dividend policy given loss-making status. Annual dividend forecast for FY2026 remains zero yen. Payout ratio calculation is not applicable given negative net income. No share buyback activity was disclosed. Total shareholder return ratio is zero percent in absence of both dividends and buybacks. The capital allocation priority clearly focuses on business investment and balance sheet restoration rather than shareholder distributions. Given negative free cash flow of -528.9 million yen and accumulated deficit of 967.9 million yen in retained earnings, near-term dividend resumption appears unlikely until sustained profitability and positive free cash flow generation are achieved. The company's shares outstanding increased from prior period, suggesting equity financing occurred during the year to support operations and investments, though specific issuance details are not provided in the financial statements. Dividend policy discussion in shareholder returns context is limited by current loss position, with management appropriately preserving cash for operational and investment needs rather than attempting premature distributions.
Execution risk on new business investments represents the primary concern, with 175.2 million yen capital expenditures concentrated in Regenerative Medicine cell culture facilities and Energy Related grid battery systems requiring successful commercialization to achieve adequate returns. The Regenerative Medicine segment absorbed 65.0 million yen operating loss on only 6.0 million yen revenue (-1084% margin), indicating multi-year investment horizon before breakeven, while regulatory approval pathways for exosome-based products remain uncertain. Cash consumption risk stems from negative operating cash flow of -357.5 million yen and negative free cash flow of -528.9 million yen requiring continued external financing access, with short-term debt concentration at 100% creating refinancing pressure within 12 months. The debt-to-equity ratio of 3.48 and minimal cash buffer of 93.3 million yen against 70.0 million yen short-term borrowings provide limited cushion against execution delays or market deterioration. SG&A structural burden risk persists with expenses at 223.5% of revenue driven by corporate overhead of 244.5 million yen, requiring either substantial revenue scaling or overhead rationalization to achieve operating breakeven, while goodwill amortization of 54.4 million yen annually represents recurring non-cash drag. Current assets increased 282.8 million yen driven primarily by PP&E build-out, creating asset impairment risk if projected returns fail to materialize, particularly given prior year's 135.4 million yen impairment in Environment Solution segment demonstrating management's willingness to recognize asset write-downs. The business model transition from established Sports operations toward development-stage biotechnology and energy storage creates technology and market acceptance risks outside core competencies.
[Industry Position] (Reference - Proprietary Analysis) J Holdings operates as a diversified holding company spanning sports facility management, environmental solutions, energy infrastructure, and regenerative medicine development. The company's profitability metrics significantly trail typical industry medians across all categories. Operating margin of -164.0% compares unfavorably to industry norms of 5-15% for mature holding companies, reflecting development-stage investment burden. ROE of -195.0% versus industry median of 8-12% for diversified holdings indicates severe profitability gap driven by both negative earnings and leveraged balance sheet structure. Equity ratio of 22.3% falls below industry median of 40-50% for holding companies, though represents improvement from prior negative equity position. The company's asset turnover of 0.354 substantially lags typical 0.8-1.2x range for holding company portfolios, suggesting capital-intensive asset base in early utilization phase. Debt-to-equity ratio of 3.48 exceeds industry median of 0.5-1.0x, indicating aggressive financial leverage relative to sector peers. Current ratio of 435.4% exceeds industry norm of 150-200%, providing relative liquidity strength despite negative operating cash flows. The company's industry positioning reflects transitional development stage characteristics rather than steady-state holding company profile, with metrics expected to converge toward industry norms as invested assets reach commercial maturity and operating leverage benefits emerge. The Sports segment margin of 27.5% aligns favorably with sports facility industry benchmarks of 20-30%, while Environment Solution's 12.5% operating margin approaches waste management industry median of 10-15%, suggesting operational competitiveness in established segments.
※ Industry: Diversified Holdings (15 companies), Comparison: Prior fiscal periods, Source: Proprietary analysis
Development-stage transition creates asymmetric risk-return profile characterized by substantial near-term cash consumption against long-term commercialization potential in regenerative medicine and energy storage markets. The equity base restoration to positive 1.19 billion yen from prior negative position through financing activities provides renewed financial foundation, though debt-to-equity ratio of 3.48 and 100% short-term debt concentration require careful refinancing management over coming 12 months. Core Sports segment demonstrates stable cash generation with 27.5% operating margin and consistent customer relationships, providing business stability anchor while development segments mature, and Environment Solution segment's turnaround to positive 8.7 million yen operating income from prior 48.8 million yen loss signals operational improvements in waste management platform. Capital expenditure program of 175.2 million yen concentrated in PP&E build-out represents 92.4% of current period revenue, indicating aggressive investment phase requiring multi-year horizon before return materialization, with ROIC metrics currently negative but expected to inflect as facilities commence revenue generation.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.